SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of June 2016
Commission File Number: 001-36621
FOAMIX PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
2 Holzman Street, Weizmann Science Park
Rehovot, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
CONTENTS
Foamix Pharmaceuticals Ltd. (the "Company") is planning to participate and present at the Jefferies 2016 Global Healthcare Conference, on June 7, 2016, and in the 2016 BIO International Convention on June 8, 2016. In preparation for these events, the Company has updated its investors' presentation, a copy of which is attached as Exhibit 99.1.
EXHIBITS
Exhibit 99.1: Foamix Pharmaceuticals Ltd. Investors Presentation
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
FOAMIX PHARMACEUTICALS LTD.
|
|
|
|
|
|
Date: June 6, 2016
|
By:
|
/s/ Ilan Hadar
|
|
|
|
Name: Ilan Hadar
|
|
|
|
Title: Chief Financial Officer
|
|
2